Fulgent Genetics (FLGT) Q2 2026: Billing Glitch Crushes Margin and Guidance
As seen on the 24/7 Wall St. homepage on July 30, 2026.
A disruptive billing system transition torpedoed Fulgent's quarter, with the EPS miss blowing past consensus by 32% as gross margin cratered to 30.1% from 42.1% year-ago. Management yanked full-year guidance to $330M–$340M revenue and flagged a $63M–$67M non-GAAP loss, citing processing delays that compressed collections just as the company was scaling pathology operations through recent acquisitions.
Continue ReadingShow less
A billing system transition derailed Fulgent Genetics in Q2 2026, pushing reported EPS to -$0.58 against a consensus estimate of -$0.44 — a miss of roughly 32%. Revenue came in at $85.4 million, falling about 7% short of the $91.8 million analysts had expected. The disruption hit collections hard, compressing gross margin to 30.1% from 42.1% in the same quarter a year earlier.
The damage was severe enough that management pulled its full-year guidance and reset expectations to $330 million–$340 million in revenue, while flagging a non-GAAP loss in the range of $63 million–$67 million. The company attributed the shortfall to processing delays tied to the billing transition arriving just as Fulgent was actively scaling its pathology operations through recent acquisitions — a combination that squeezed cash collections at a particularly costly moment.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
The quarter marks a sharp contrast to the six periods before Q1 2026, during which Fulgent consistently beat a cautious Street. Q1 2026 was the first crack in that streak, with EPS of -$0.36 just barely missing the -$0.35 estimate. The Q2 result deepens that reversal, and investors will be watching whether the billing issues prove temporary or signal a more persistent drag as the pathology buildout matures.
Mentioned: FLGT